Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M168,544Revenue (TTM) $M39,907Net Margin (%)13.8Altman Z-Score3.3
Enterprise Value $M180,833EPS (TTM) $2.0Operating Margin %19.6Piotroski F-Score7
P/E(ttm)31.4Beneish M-Score-2.6Pre-tax Margin (%)17.1Higher ROA y-yN
Price/Book3.910-y EBITDA Growth Rate %5.4Quick Ratio1.6Cash flow > EarningsY
Price/Sales4.35-y EBITDA Growth Rate %9.2Current Ratio1.9Lower Leverage y-yN
Price/Free Cash Flow18.4y-y EBITDA Growth Rate %-41.1ROA % (ttm)5.5Higher Current Ratio y-yY
Dividend Yield %3.0PEG3.4ROE % (ttm)12.4Less Shares Outstanding y-yY
Payout Ratio %94.0Shares Outstanding M2,757ROIC % (ttm)11.3Gross Margin Increase y-yY

Gurus Latest Trades with MRK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKBarrow, Hanley, Mewhinney & Strauss 2016-09-30 Reduce-0.7%$57.65 - $63.86
($61.28)
$ 61.13-0%Reduce -29.93%18,581,032
MRKVanguard Health Care Fund 2016-09-30 Reduce-0.61%$57.65 - $63.86
($61.28)
$ 61.13-0%Reduce -10.72%41,516,228
MRKDodge & Cox 2016-09-30 Reduce-0.34%$57.65 - $63.86
($61.28)
$ 61.13-0%Reduce -24.80%18,327,311
MRKJoel Greenblatt 2016-09-30 Reduce-0.14%$57.65 - $63.86
($61.28)
$ 61.13-0%Reduce -38.77%330,785
MRKKahn Brothers 2016-09-30 Reduce-0.08%$57.65 - $63.86
($61.28)
$ 61.13-0%Reduce -0.72%957,991
MRKCharles Brandes 2016-09-30 Reduce-0.07%$57.65 - $63.86
($61.28)
$ 61.13-0%Reduce -2.75%2,812,318
MRKT Rowe Price Equity Income Fund 2016-09-30 Reduce-0.03%$57.65 - $63.86
($61.28)
$ 61.13-0%Reduce -3.57%3,375,000
MRKKen Fisher 2016-09-30 Add0.01%$57.65 - $63.86
($61.28)
$ 61.13-0%Add 0.86%6,817,544
MRKTweedy Browne 2016-09-30 Buy 0.01%$57.65 - $63.86
($61.28)
$ 61.13-0%New holding3,306
MRKMario Gabelli 2016-09-30 Reduce$57.65 - $63.86
($61.28)
$ 61.13-0%Reduce -5.37%107,405
MRKRichard Pzena 2016-09-30 Reduce$57.65 - $63.86
($61.28)
$ 61.13-0%Reduce -0.47%1,408,678
MRKRuane Cunniff 2016-09-30 Sold Out $57.65 - $63.86
($61.28)
$ 61.13-0%Sold Out0
MRKJoel Greenblatt 2016-06-30 Reduce-0.42%$52.91 - $57.68
($55.73)
$ 61.1310%Reduce -56.73%540,222
MRKT Rowe Price Equity Income Fund 2016-06-30 Reduce-0.3%$52.91 - $57.68
($55.73)
$ 61.1310%Reduce -25.58%3,500,000
MRKVanguard Health Care Fund 2016-06-30 Reduce-0.26%$52.91 - $57.68
($55.73)
$ 61.1310%Reduce -4.57%46,499,820
MRKKahn Brothers 2016-06-30 Reduce-0.2%$52.91 - $57.68
($55.73)
$ 61.1310%Reduce -2.08%964,925
MRKRichard Pzena 2016-06-30 Add0.18%$52.91 - $57.68
($55.73)
$ 61.1310%Add 53.62%1,415,390
MRKCharles Brandes 2016-06-30 Reduce-0.08%$52.91 - $57.68
($55.73)
$ 61.1310%Reduce -3.60%2,891,914
MRKBarrow, Hanley, Mewhinney & Strauss 2016-06-30 Reduce-0.01%$52.91 - $57.68
($55.73)
$ 61.1310%Reduce -0.55%26,516,070
MRKKen Fisher 2016-06-30 Add0.01%$52.91 - $57.68
($55.73)
$ 61.1310%Add 0.91%6,759,345
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FRAZIER KENNETH CChairman, President & CEO 2016-11-10Sell140,000$65.03-6view
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy 2016-11-07Sell85,523$60.021.85view
LAZARUS ROCHELLE BDirector 2016-11-02Sell20,000$59.063.5view
WENDELL PETER CDirector 2016-11-02Sell5,000$59.52.74view
GRADDICK WEIR MIRIAN MExe V-P, HR 2016-10-03Sell40,800$62.07-1.51view
Schechter Adam HEVP & Pres-Global Human Health 2016-09-01Sell39,200$62.61-2.36view
Golestani ClarkEVP & Chief Info Officer 2016-08-10Sell3,000$63.03-3.01view
FRAZIER KENNETH CChairman, President & CEO 2016-08-05Sell392,000$61.81-1.1view
GRADDICK WEIR MIRIAN MExe V-P, HR 2016-07-05Sell45,000$57.995.41view
FRAZIER KENNETH CChairman, President & CEO 2016-07-05Sell60,000$585.4view

Press Releases about MRK :

Quarterly/Annual Reports about MRK:

News about mrk:

Articles On GuruFocus.com
US Market Indexes Lower With Gains for the Week Nov 18 2016 
Stan Druckenmiller Axes Halliburton, Gains 5 New Positions Nov 17 2016 
Stocks Lower on Wednesday After Election Gains Nov 16 2016 
Merck Reports Triple-Combo Results Nov 14 2016 
Insiders Are Buying Hertz and Selling Merck Nov 11 2016 
3 Health Industry Sectors Bound to Profit From a Trump Presidency Nov 11 2016 
Merck Announces 3rd-Quarter Results Oct 25 2016 
Buy Merck on Drops to $60 Oct 16 2016 
US Market Indexes Lower on Tuesday Oct 11 2016 
Oil Prices Help Stock Valuations on Monday Oct 10 2016 

More From Other Websites
Tech Data’s board gets more diverse with addition of former Merck executive Dec 02 2016
Merck & Co., Inc. (MRK) Gets Coveted Approval For Keytruda Dec 02 2016
AbbVie’s Venclexta May Become Promising Multiple Myeloma Therapy Dec 02 2016
Acute Myeloid Leukemia: Growth Opportuny for AbbVie’s Venclexta? Dec 02 2016
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma Dec 02 2016
Merck KGaA (MKGAF) Expands Distribution Deal with Roche Dec 02 2016
Keytruda Is Merck’s Immuno-Oncology Business Dec 02 2016
Label Expansion May Boost Venclexta’s Growth Prospects Dec 02 2016
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda Dec 02 2016
Merck wins UK okay for Keytruda in lung cancer after price cut Dec 01 2016
Pharma execs weigh in on possible changes under Trump Dec 01 2016
Recent R&D Developments from Merck You Won’t Want to Miss Dec 01 2016
What’s Forcing Valeant to Sell Its Core Assets? Dec 01 2016
Bringing foreign drugs into the US market is a dangerous ... Dec 01 2016
Alexandria Real Estate, Merck Ink Long-Term Pharma Lease Dec 01 2016
FDA Grants Priority Review to Supplemental Biologics License Application (sBLA) for Merck’s... Dec 01 2016
AbbVie’s Plans for ABT-555, a Novel Multiple Sclerosis Therapy Dec 01 2016
Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study Dec 01 2016
Inside Merck’s Business Segment-Wise Performance Dec 01 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)